-- Aerinaze (desloratadine 2.5 mg/pseudoephedrine sulphate 120 mg), from Schering-Plough Europe, for the symptomatic treatment of seasonal allergic rhinitis, accompanied by nasal congestion. EMEA review began on 26 July 2006 with an active review time of 196 days. [click link for full article]
From: www.medicalnewstoday.com
EMEA CMPH Use Adopts 5 Positive Opinions Recommending The Granting Of A Marketing Authorisation For The Following ...
Posted by Ruslan Abuzant at 2:08 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment